Last SFr.31.65 CHF
Change Today -0.95 / -2.91%
Volume 70.2K
NWRN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
OTC US
As of 6:23 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

newron pharmaceuticals spa (NWRN) Snapshot

Open
SFr.32.90
Previous Close
SFr.32.60
Day High
SFr.33.25
Day Low
SFr.31.55
52 Week High
03/3/15 - SFr.35.85
52 Week Low
04/16/14 - SFr.12.65
Market Cap
413.2M
Average Volume 10 Days
137.8K
EPS TTM
SFr.-0.80
Shares Outstanding
13.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEWRON PHARMACEUTICALS SPA (NWRN)

Related News

No related news articles were found.

newron pharmaceuticals spa (NWRN) Related Businessweek News

No Related Businessweek News Found

newron pharmaceuticals spa (NWRN) Details

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the discovery and development of drugs for the treatment of central nervous system disorders and pain. Its lead product is safinamide that has completed Phase III trials for the treatment of patients with Parkinson’s disease. The company also has a pipeline of novel drug candidates in Phase II trials, which include sNN0031 for the treatment of Parkinson’s disease patients, sNN0029 for the treatment of amyotrophic lateral sclerosis, and Sarizotan for the treatment of Rett’s syndrome. In addition, it develops NW-3509 that is in Phase I trials for the treatment of schizophrenia; and ralfinamide, which is in Phase II trials for the treatment of neuropathic pain. It has a collaboration agreement with Meiji Seika Pharma Co., Ltd. for the development of safinamide in Japan and Asia. Newron Pharmaceuticals S.p.A. was founded in 1998 and is headquartered in Bresso, Italy.

23 Employees
Last Reported Date: 03/4/14
Founded in 1998

newron pharmaceuticals spa (NWRN) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: €390.0K
Chief Medical Officer
Total Annual Compensation: €752.0K
Compensation as of Fiscal Year 2013.

newron pharmaceuticals spa (NWRN) Key Developments

Zambon Company S.p.A. and Newron Pharmaceuticals Announce EU Commission Approves Xadago® (Safinamide) for Mid-Late Stage PD Patients

Zambon Company S.p.A. and its partner Newron Pharmaceuticals S.p.A. announced that the European Commission approved the use of Xadago® (safinamide) for the treatment of idiopathic Parkinsonâ s disease (PD). Xadago® has been approved for mid-to late-stage fluctuating patients as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products. The decision follows the Positive Opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on December 18th, 2014 and is applicable to all 28 European Union member countries, as well as Iceland, Liechtenstein and Norway.

Newron Pharmaceuticals S.p.A. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:25 PM

Newron Pharmaceuticals S.p.A. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:25 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Stefan Weber, Chief Executive Officer, Managing Director and Executive Director.

Newron Pharmaceuticals S.p.A. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 04:00 PM

Newron Pharmaceuticals S.p.A. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 04:00 PM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Stefan Weber, Chief Executive Officer, Managing Director and Executive Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NWRN:SW SFr.31.65 CHF -0.95

NWRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NWRN.
View Industry Companies
 

Industry Analysis

NWRN

Industry Average

Valuation NWRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 117.3x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 112.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEWRON PHARMACEUTICALS SPA, please visit www.newron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.